23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial
Top Cited Papers
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 355 (9221), 2106-2111
- https://doi.org/10.1016/s0140-6736(00)02377-1
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Pneumococcal vaccination in HIV-1-infected adults in UgandaAIDS, 1998
- Clinical Efficacy of Pneumococcal Vaccine in the ElderlyAmerican Journal Of Medicine, 1997
- Increased Plasma Human Immunodeficiency Virus Type 1 Burden following Antigenic Challenge with Pneumococcal VaccineThe Journal of Infectious Diseases, 1996
- Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 1996
- Risk Factors for Pneumococcal Disease in Human Immunodeficiency Virus-Infected PatientsThe Journal of Infectious Diseases, 1996
- Antibody Class and Subclass Responses to Pneumococcal Polysaccharides following Immunization of Human Immunodeficiency Virus-Infected PatientsThe Journal of Infectious Diseases, 1995
- Pneumococcal and influenza vaccination levels among HIV-infected adolescents and adults receiving medical care in the United StatesAIDS, 1994
- HIV-1 incidence and HIV-1 -associated mortality in a rural Ugandan population cohortAIDS, 1994
- Class-Specific Antibody Response to Pneumococcal Capsular Polysaccharides in Men Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1988
- Efficacy of Pneumococcal Vaccine in High-Risk PatientsNew England Journal of Medicine, 1986